高海拔适应和心血管疾病风险之间的关联:双向的门德尔随机化研究
Yuqing Jiang1, Jie Ping2, Hao Lu2
1Collaborative Innovation Center for Personalized Cancer Medicine, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing City, Jiangsu Province, 211166, People's Republic of China.
Molecular genetics and genomics : MGG
|May 26, 2023
概括
高海拔适应 (HAA) 因果降低了冠状动脉疾病 (CAD) 的风险. 这项研究没有发现任何证据表明心血管疾病 (CVD) 影响HAA,为CAD预防策略提供了见解.
科学领域:
- 遗传学 遗传学 是一个
- 心血管医学 心血管医学
- 人类的适应能力
背景情况:
- 高海拔适应 (HAA) 与较低的心血管疾病 (CVD) 风险有关.
- 在HAA和心血管疾病之间的因果关系和方向性仍然不清楚.
研究的目的:
- 使用孟德尔随机化研究HAA和六种主要心血管疾病之间的潜在因果关系.
- 为了确定HAA是否影响冠状动脉疾病 (CAD),脑动脉瘤,缺血性中风,外周动脉疾病,心律失常和心房动的风险.
主要方法:
- 使用双样双向门德尔随机化 (MR) 与全基因组关联研究总结数据.
- 进行了敏感性分析,包括MR-Egger回归,MR-PRESSO,Cochran的Q测试,以及留出一个的分析,以确保稳定性和评估性.
主要成果:
- 基因预测的HAA显示了与降低CAD风险的显著因果关系 (OR=0.029).
- 在心血管疾病和HAA之间没有发现统计学上显著的因果关系,反之亦然.
结论:
- HAA对患有CAD的风险具有因果保护作用.
- 有证据表明,心血管疾病不会对HAA产生因果影响,支持HAA作为CAD预防的因素.
相关概念视频
Coronary Artery Disease I: Introduction
34
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
34
Psychoneuroimmunology: Cardiovascular Disease
57
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
A key area of focus in PNI is the relationship between stress and coronary...
57
Hypertension and Regulation of Blood Pressure
2.2K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.2K
Coronary Artery Disease IV: Preventive Measures
25
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
25
Mitral Regurgitation I: Introduction
20
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
20
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
472
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
472


